(5-Chlorofuran-2-yl)boronic acid | 1354827-99-8

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: (5-Chlorofuran-2-yl)boronic acid
• CAS: 1354827-99-8
• 化学式: C₄H₄BClO₃
• 分子量: 146.338
• InChiKey: PJPIFUJOHVETNR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.39
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  53.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,8 - 二溴二苯并呋喃 、 (5-Chlorofuran-2-yl)boronic acid 在 bis-triphenylphosphine-palladium(II) chloride 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 以85%的产率得到
  参考文献：
  名称：

  CN114874169

  摘要：

  公开号：

文献信息

• Photoinduced [3+2] Cycloaddition of Carbenes and Nitriles: A Versatile Approach to Oxazole Synthesis
  作者：Argha Saha、Chiranjit Sen、Srimanta Guin、Chandan Das、Debajit Maiti、Subhabrata Sen、Debabrata Maiti

  DOI：10.1002/anie.202308916

  日期：2023.11.27

  we developed a versatile method for [3+2] cycloaddition with diverse nitriles to yield substituted oxazoles. Our approach can be extended to bis-oxazoles, isotope-labeled oxazoles, drug diversification, as well as natural product and drug synthesis. Integration of photolysis with continuous-flow chemistry demonstrated applicability, scalability, and robustness for oxazole synthesis.

  利用单线态卡宾，我们开发了一种与多种腈进行[3+2]环加成反应以产生取代恶唑的通用方法。我们的方法可以扩展到双恶唑、同位素标记恶唑、药物多样化以及天然产物和药物合成。光解与连续流化学的集成证明了恶唑合成的适用性、可扩展性和稳健性。
• Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD)
  作者：Yuchuan Wu、Jianchang Li、Junjun Wu、Paul Morgan、Xin Xu、Fabio Rancati、Stefania Vallese、Luca Raveglia、Rajeev Hotchandani、Nathan Fuller、Joel Bard、Kristina Cunningham、Susan Fish、Rustem Krykbaev、Steve Tam、Samuel J. Goldman、Cara Williams、Tarek S. Mansour、Eddine Saiah、Joseph Sypek、Wei Li

  DOI：10.1016/j.bmcl.2011.11.046

  日期：2012.1

  Chronic obstructive pulmonary disease (COPD) is an inflammatory lung disease associated with irreversible progressive airflow limitation. Matrix metalloproteinase-12 (MMP-12) has been characterized to be one of the major proteolytic enzymes to induce airway remodeling, destruction of elastin and the aberrant remodeling of damaged alveoli in COPD and asthma. The goal of this project is to develop and identify an orally potent and selective small molecule inhibitor of MMP-12 for treatment of COPD and asthma. Syntheses and structure-activity relationship (SAR) studies of a series of dibenzofuran (DBF) sulfonamides as MMP-12 inhibitors are described. Potent inhibitors of MMP-12 with excellent selectivity against other MMPs were identified. Compound 26 (MMP118), which exhibits excellent oral efficacy in the MMP-12 induced ear-swelling inflammation and lung inflammation mouse models, had been successfully advanced into Development Track status. (C) 2011 Elsevier Ltd. All rights reserved.